Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises

被引：0

作者：

Mohammed Z. Allouh ^{[1
]}

Syed Faizan Ali Rizvi ^{[2
]}

Ali Alamri ^{[2
]}

Yusuf Jimoh ^{[3
]}

Salma Aouda ^{[2
]}

Zakaria H. Ouda ^{[3
]}

Mohammad I. K. Hamad ^{[2
]}

Mick Perez-Cruet ^{[3
]}

G. Rasul Chaudhry ^{[4
]}

机构：

[1] Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, P. O. Box: 15551, Al Ain

[2] OU-WB Institute for Stem Cell and Regenerative Medicine, Oakland University, Rochester, 48309, MI

[3] Department of Biological Sciences, Oakland University, Rochester, 48309, MI

[4] College of Medicine and Health Sciences, Khalifa University, Abu Dhabi

[5] Department of Neurosurgery, Corewell Health, Royal Oak, MI

来源：

Stem Cell Research & Therapy | / 16卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Degenerative disease; Multipotent; Progenitor cells; Regenerative medicine; Stem cells;

D O I：

10.1186/s13287-025-04254-0

中图分类号：

学科分类号：

摘要：

The use of mesenchymal stem cells (MSCs) from perinatal tissue sources has gained attention due to their availability and lack of significant ethical or moral concerns. These cells have a higher proliferative capability than adult MSCs and less immunogenic or tumorigenesis risk than fetal and embryonic stem cells. Additionally, they do not require invasive isolation methods like fetal and adult MSCs. We reviewed the main biological and therapeutic aspects of perinatal MSCs in a three-part article. In the first part, we revised the main biological features and characteristics of MSCs and the advantages of perinatal MSCs over other types of SCs. In the second part, we provided a detailed molecular background for the main biomarkers that can be used to identify MSCs. In the final part, we appraised the therapeutic application of perinatal MSCs in four major degenerative disorders: degenerative disc disease, retinal degenerative diseases, ischemic heart disease, and neurodegenerative diseases. In conclusion, there is no single specific molecular marker to identify MSCs. We recommend using at least two positive markers of stemness (CD29, CD73, CD90, or CD105) and two negative markers (CD34, CD45, or CD14) to exclude the hematopoietic origin. Moreover, utilizing perinatal MSCs for managing degenerative diseases presents a promising therapeutic approach. This review emphasizes the significance of employing more specialized progenitor cells that originated from the perinatal MSCs. The review provides scientific evidence from the literature that applying these progenitor cells in therapeutic procedures provides a greater regenerative capacity than the original primitive MSCs. Finally, this review provides a valuable reference for researchers exploring perinatal MSCs and their therapeutic applications. © The Author(s) 2025.

引用

共 160 条

[41]

Balzano F., Bellu E., Basoli V., Dei Giudici S., Santaniello S., Cruciani S., Et al., Lessons from human umbilical cord: gender differences in stem cells from Wharton’s jelly, Eur J Obstet Gynecol Reprod Biol, 234, pp. 143-148, (2019)

[42]

Pirjali T., Azarpira N., Ayatollahi M., Aghdaie M.H., Geramizadeh B., Talai T., Isolation and characterization of human mesenchymal stem cells derived from human umbilical cord Wharton’s jelly and amniotic membrane, Int J Organ Transpl Med, 4, pp. 111-116, (2013)

[43]

Song Y., Lim J.-Y., Lim T., Im K.-I., Kim N., Nam Y.-S., Et al., Human mesenchymal stem cells derived from umbilical cord and bone marrow exert Immunomodulatory effects in different mechanisms, World J Stem Cells, 12, pp. 1032-1049, (2020)

[44]

Han S., Zhao Y., Xiao Z., Han J., Chen B., Chen L., Et al., The three-dimensional collagen scaffold improves the stemness of rat bone marrow mesenchymal stem cells, J Genet Genomics Yi Chuan Xue Bao, 39, pp. 633-641, (2012)

[45]

Riekstina U., Cakstina I., Parfejevs V., Hoogduijn M., Jankovskis G., Muiznieks I., Et al., Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis, Stem Cell Rev Rep, 5, pp. 378-386, (2009)

[46]

Tsai C.-C., Su P.-F., Huang Y.-F., Yew T.-L., Hung S.-C., Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells, Mol Cell, 47, pp. 169-182, (2012)

[47]

Liu T.M., Wu Y.N., Guo X.M., Hui J.H.P., Lee E.H., Lim B., Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells, Stem Cells Dev, 18, pp. 1013-1022, (2009)

[48]

Greco S.J., Liu K., Rameshwar P., Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells, Stem Cells Dayt Ohio, 25, pp. 3143-3154, (2007)

[49]

Seo K.-W., Lee S.-R., Bhandari D.R., Roh K.-H., Park S.-B., So A.-Y., Et al., OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs), Biochem Biophys Res Commun, 384, pp. 120-125, (2009)

[50]

Davies O.G., Cooper P.R., Shelton R.M., Smith A.J., Scheven B.A., Isolation of adipose and bone marrow mesenchymal stem cells using CD29 and CD90 modifies their capacity for osteogenic and adipogenic differentiation, J Tissue Eng, 6, (2015)

← 1 2 3 4 5 6 7 8 9 10 →